Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 17;4(Suppl 4):e000529.
doi: 10.1136/esmoopen-2019-000529. eCollection 2019.

How I treat cancer: treatment of rheumatological side effects of immunotherapy

Karolina Benesova  1 , Hanns-Martin Lorenz  2 , Jan Leipe  3 , Karin Jordan  2
Affiliations
Review

How I treat cancer: treatment of rheumatological side effects of immunotherapy

Karolina Benesova et al. ESMO Open. .
No abstract available

Keywords: immunotherapy; rheumatic irAEs.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KB: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, BMS, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, UCB. Scientific support: Abbvie, Novartis. H-ML: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly. Scientific support and/or educational seminars and/or clinical studies: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, Thermo Fisher. JL: Consultancy and speaker fees: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Scientific support: Novartis, Pfizer. KJ: Consultancy and/or speaker fees: MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-med.

Figures

Figure 1
Figure 1
Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying antirheumatic drugs) can take up to 12 weeks until onset of therapeutic response. †Consultation of a rheumatologist should be considered. ‡Timely consultation of a rheumatologist is strongly recommended. bDMARDs, biological DMARDs; csDMARDs, conventional synthetic DMARDs; ICPi, immune checkpoint inhibitors; IACS, intra-articular corticosteroid injections; IL-6, Interleukin 6; NSAID, non-steroidal anti-inflammatory drug; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; TNFα, tumour necrosis factor α.
See this image and copyright information in PMC

References

    1. Buder-Bakhaya K, Benesova K, Schulz C, et al. . Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 2018;67:175–82. 10.1007/s00262-017-2069-9 - DOI - PMC - PubMed
    1. Kostine M, Rouxel L, Barnetche T, et al. . Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2018;77:393–8. 10.1136/annrheumdis-2017-212257 - DOI - PubMed
    1. Puzanov I, Diab A, Abdallah K, et al. . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working Group. J Immunother Cancer 2017;5 10.1186/s40425-017-0300-z - DOI - PMC - PubMed
    1. Cappelli LC, Gutierrez AK, Bingham CO, et al. . Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res 2017;69:1751–63. 10.1002/acr.23177 - DOI - PMC - PubMed
    1. Jordan K, Aapro M, Kaasa S, et al. . European Society for medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol 2018;29:36–43. 10.1093/annonc/mdx757 - DOI - PubMed

LinkOut - more resources